Latest News and Press Releases

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech,...

Madison, Wisconsin, July 29, 2025 (GLOBE NEWSWIRE) -- The Wisconsin Economic Development Corporation (WEDC) has approved a 25% tax credit for investors in a groundbreaking diabetes cure being...

SAB BIO Announces Oversubscribed $175 Million Private Placement

ALPHARETTA, Ga., July 08, 2025 (GLOBE NEWSWIRE) -- Heald, the human-led, tech-enabled platform redefining diabetes care, proudly announces that Dr. Neal Patel, Chief Informatics Officer at...

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646 participant visits, including both...

CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the U.S. and Belgium, was recognized at the American Diabetes Association’s 85th...

Abvance closes seed round led by Zubi Capital to advance glucagon-based therapies aimed at preventing hypoglycemia in people with diabetes.

MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss.No...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass,...

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia